Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1269-1275

  Jager, J J ^a,b   Jansen, R L H ^c   Arends, J W ^c   Joosten Achjanie, S ^c   Volovics, L ^c   Schouten, L J ^c   De Jong, J M A ^c   Meyenfeldt, M F V ^c   Blijham, G H ^c  

^a MAASTRO CLINIC   (Netherlands)

^b Radiotherapeutisch Instituut Limburg   (Netherlands)

^c NONE

Author keywords

Bcl 2; Breast cancer; Locoregional recurrence; MIB 1; p53

Indexed keywords

CD44V ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MEDROXYPROGESTERONE ACETATE; MIB 1; PROTEIN BCL 2; PROTEIN P53; PROTEIN PS2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD44; ANTIGENS, NUCLEAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENETIC MARKERS; GLYCOPROTEINS; HUMANS; KI-67 ANTIGEN; MASTECTOMY, MODIFIED RADICAL; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PHENOTYPE; PLOIDIES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0034093608     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Johansen H, Kaae S, Schiødt: Simple mastectomy with postoperative irradiation versus extended radical mastectomy in breast cancer. Acta Oncol 29: 709-715, 1990.
2. Wallgren A, Arner O, Bergstrøm J, Blomstedt B, Granberg P-O, Räf L, Silversward C, Einhorn J: Radiation therapy in operable breast cancer: results from the Stockholm trial on adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 12: 533-537, 1986.
3. Høst H, Brennhovd IO, Loeb M: Postoperative radiotherapy in breast cancer-Long-term results from the Oslo study. Int J Radiat Oncol Biol Phys 12: 727-732, 1986.
4. Cancer Research Campaign Working Party: Cancer research campaign (King's/Cambridge) trial for early breast cancer. The Lancet 12: 55-60, 1980.
5. Fowble B, Gray R, Gilchrist K, Goodman RL, Taylor S, Tormey DC: Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6: 1107-1117, 1988.
6. Griem KL, Henderson IC, Gelman R, Ascoli D, Silver B, Recht A, Goodman RL, Hellman S, Harris JR: The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 5: 1546-1555, 1987.
7. Rutqvist LE, Pettersson D, Johansson H: Adjuvant radiation therapy versus surgery alone in operable breast cancer: long-term follow-up of a randomized clinical trial. Radiother Oncol 26: 104-110, 1993.
8. Janjan NA, McNeese MD, Buzdar AU, Montague ED, Oswald MJ: Management of locoregional recurrent breast cancer. Cancer 58: 1552-1556, 1986.
9. Fowble B, Click J, Goodman R: Radiotherapy for the prevention of loco-regional recurrence in high risk patients post mastectomy receiving adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 15: 627-631, 1988.
10. Uematsu M, Bornstein BA, Recht A, Abner A, Come SE, Shulman LN, Silver B, Harris JR: Long-term results of postoperative radiation therapy following mastectomy with orwithout chemotherapy in stage 1-III breast cancer. Int J Radiat Oncol Biol Phys 25: 765-770, 1993.
11. Hamilton CS, Nield JM, Adler GF, Clingan PR: Results of breast conserving treatment of breast cancer. Acta Oncol 29: 137-142, 1990.
12. Larson D, Weinstein M, Goldberg I, Silver B, Recht A, Cady B, Silen W, Harris JR: Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 12: 1575-1582, 1986.
13. Rytton N, Holm NV, Qvist N, Blichert-Toft M: Influence of adjuvant irradiation on the development of late arm lymphedema and impaired shoulder mobility after mastectomy for carcinoma of the breast. Acta Oncol 27: 667-670, 1988.
14. Jansen RLH, Hillen HFP, Schouten HC: Prognostic and predictive factors in breast cancer. Netherlands J Med 51: 65-77, 1997.
15. Hupperets PSGJ, Wils JAJM, Volovics L, Schouten L, Fickers MMF, Bron HNLM, Schouten HC, Jager JJ, de Jong JMA, Hillen HFP, Blijham GH: Adjuvant chemo-hormonal therapy with cyclofosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Annals Oncol 4: 245-301, 1993.
16. Scatchard G: The attraction of proteins from small molecules and ions. Ann NY Ac Sci 51: 660-672, 1949.
17. Schutte B, Reynders MMJ, Bosman FT, Blijham GH: Flow cytometry determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytomtery 6: 26-30, 1985.
18. Hedley DW: Flow cytometry using paraffin-embedded tissue: five years on. Cytometry 10: 229-241, 1989.
19. Vindeløv L, Christensen U, Nissen NI: A detergent trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 5: 408-419, 1984.
20. Hiddemann W, Schumann J, Andreef M, Barlogie B, Herman CJ, Leif RC, Mayal BH, Murphy RF, Sanberg M: Convention of nomenclature for DNA cytometry. Cancer Genet Cytogenet 13: 181-183, 1984.
21. Jansen RLH, Joosten-Achjanie SR, Volovics A, Arends JW, Hupperets PSGJ, Hillen HFP, Schouten HC: Relevance of the expression of bcl-2 in combination with pS3 as a prognostic factor in breast cancer. Anticancer Res 18: 4455-4462, 1998.
22. Jansen RLH, Hupperets PSGJ, Arends JW, Joosten-Achjanic SR, Volovics A, Hillen HFP, Schouten HC: PS2 is an independent factor for post-relapse survival in primary breast cancer. Anticancer Res 18: 577-582, 1998.
23. Jansen RHL, Joosten-Achjanie SR, Arenas JW, Volovics A, Hupperets PSGJ, Scheuten HC, Hillen HFP: CD44v6 is not a prognostic (actor in primary breast cancer. Annals Oncol 9: 109-111, 1998.
24. Andersen PK, Borgan Ø, Gill RD, Keiding N: Statistical models based on counting processes. New York: Springer-Verlag, 1993.
25. Coleman CN: Of what use is molecular biology to the practising radiation oncologist. Radiather Oncol 46: 117-125, 1998.
26. Stenmark-Askmalm M, Stäl O, Olsen K, NordenskJold B, South-East Sweden Breast Cancer Group: p53 as a prognostic factor in stage 1 breast cancer. Br J Cancer 72: 715-719, 1945.
27. Silvestrini R, Bcnini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, DI Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970, 1993.
28. Levesque MA, Clark GM, Yu H, Diamandis EP: Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. Br J Cancer 72: 720-727, 1995.
29. McGuire WL, Clark GM: Prognostic factors and treatment in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992.
30. Lee AKC, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K: Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a, bN0MO). Cancer 79: 761-771, 1997.
31. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O, Barareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and pcritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454-466, 1994.
32. Friedrichs K, Gluba S, Eidtmann H, Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647, 1993.
33. Soddu S, Sacchi A: p53 role in DNA repair and tumorgenesis. Exp Clin Cancer Res 16: 237-242, 1997.
34. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Mark E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995.
35. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
36. Tubiana M, Courdi A: Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol 15: 1-18, 1989.
37. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61: 420-427, 1988.
38. Coulson PB, Thornthwaite JT, Woolley TW, Sugarbaker EV, Seckinger D: Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer res 44: 4187-4196, 1984.
39. Ewers S-B, Baldetorp B, Killander D, Långstrøm E: Flow cytometry DNA ploidy and nuber of cell populations in the primary breast cancer and their correlation to the prognosis. Acta Oncol 28: 913-918, 1989.
40. Bosari S, Lee AKC, Tahan SR, Figoni MAT, Wiley BD, Heatley GJ, Silvermann ML: DNA flow cytometric analysis and prognosis of axillary lymph node-negative hreast carcinoma. Cancer 70: 1443-1450, 1992.
41. Stanton PD, Cooke TG, Oakes SJ, Winstanley J, Holt S, George WD, Murray GD: Lack of prognostic significance of DNA ploidy and S phase fraction in hreast cancer. Br J Cancer 66: 425-429, 1992.
42. Stäl O, Carstensen J, Hatschek T, Nordenskjøld B: Significance of S-phase fraction and hormone receptor content in the management of young hreast cancer patients. Br J Cancer 66: 706-711, 1992.
43. Clark GM, Mathieu M-C, Owens MA, Dressier LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Aheloff MD, McGuire WL: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10: 428-432, 1992.
44. Wintzer H-O, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421-428, 1991.
45. Silvestrini R, Daidone MG, Luisi P, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13: 697-704, 1995.
46. Railo M, Nording S, von Boguslawsky K, Leivonen M, Kyllonen L, Smitten K: Prognostic value of Ki-67 immunolahelling in primary operable breast cancer. BrJ Cancer 68: 579-583, 1993.
47. Sahin M, Ro J, Ro JY, Blick MB, El-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala UG: Ki-67 immunostaining in node-negative stage I/II beast carcinoma. Cancer 68: 549-557, 1991.
48. Pinder SE, Wencyk P, sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JFR, Blarney RW, Ellis IO: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71: 146-149, 1995.
49. Veronese SM, Gambacorta M, Gottarde O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926-3931, 1993.
50. Haffty BG, Toth M, Flynn S, Fischer D, Carter D: Prognostic value of DNA flow cytometry in the locally recurrent, conservatively treated breast cancer patient. J Clin Oncol 10: 1839-1847, 1992.
51. Ewers S-B, Attewell R, Baldetorp B, Borg Å, Fernö M, Långström, Rydèn S, Killander D: Flow cytometry DNA analysis and prediction of loco-regional recurrences after mastectomy in breast cancer. Acta Oncol 31: 733-740, 1992.
52. Soubeyran I, Quénel, Coindre J-M, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifcn in postmenopausal breast cancer patients. Br J Cancer 74: 1120-1125, 1996.
53. Johnston SR, Saccani-Jotti G, Smith IE, Newby J, Dowsett M: Discordance between PS2 and ER expression in tamoxifen resistant breast cancer (Meeting abstract). Breast Cancer Res Treat (37 suppl): 33, 1996.
54. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut MN, Allasia C: Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 28: 289-296, 1997.